Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients
Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- standard gadolinium contrast
Who could take part
Relapsing and progressive · 20 to 70
Show the full criteria
Inclusion criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- * Diagnosis of multiple sclerosis Relapsing-remitting defined as 2 exacerbations and a worsening of neurologic function over 1 day followed by at least 30 days of no progression OR Secondary-progressive defined as increase of at least 1.0 unit on Expanded Disability Status Scale (EDSS) in past 2 years with or without exacerbations --Prior/Concurrent Therapy-- * Biologic therapy: Prior interferon beta 1A, 1B, or glatiramer acetate No concurrent interferon beta 1A, 1B, or glatiramer acetate * Endocrine therapy: Concurrent oral and IV corticosteroids allowed --Patient Characteristics-- * Performance status: EDSS no greater than 7.0 * Hematopoietic: No hematologic dysfunction including hemolytic anemia * Hepatic: No hepatic dysfunction * Renal: No renal dysfunction * Cardiovascular: No cardiac pacemaker * Other: Not pregnant or nursing Negative pregnancy test No intracranial clips, metal implants, or external clips within 10 mm of head No metal in eyes No known gadolinium texaphyrin allergy No known claustrophobia
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization transfer ratio histogram parameters, and correlate these measurements with clinical measures of disability in patients with multiple sclerosis. II. Measure the quantity of whole brain N-acetylaspartate in patients with multiple sclerosis and compare these values to those from age matched controls. III. Determine the correlation between specific neuropsychological tests which assess global cognitive functioning and the quantitative measurements taken in these patients in this study.
Loading reviews and guidelines…
Related trials
- Glucose Consumption in MS Using [F-18]FDG-PET
Phase 4 · Recruiting
Still running
- Assessment of Synaptic Density in MS
Early phase 1 · Recruiting
Still running
- Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Inves
Not a drug-phase study · Status unknown
No results found
- Role of Microglial Activation and Norepinephrine Transporter Abnormali
Phase 1 / Phase 2 · Completed
Results posted, not judged
- PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Othe
Phase 1 / Phase 2 · Recruiting
Still running
- Imaging of Intracerebral Inflammation in MS
Not a drug-phase study · Completed
Paper found, not read
History
Started
Apr 1999